Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies.
Details
Serval ID
serval:BIB_59BC34AC961A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies.
Journal
BioMed research international
ISSN
2314-6141 (Electronic)
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
2014
Pages
489536
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
To assess through a systematic review and meta-analysis of the literature the prognostic implication of sentinel lymph node mapping in Merkel cell carcinoma (MCC).
PubMed and SCOPUS databases were searched by using "Merkel AND sentinel" as keywords. All studies with prognostic information regarding SLN mapping in cN0 MCC patients were included. Hazard ratio (HR) for overall survival (OS) and disease free survival (DFS) was used as effect size.
SLN biopsy predicted better DFS and OS as compared to the nodal observation in cN0 MCC patients (pooled HR for DFS: 1.61 (95% CI: 1.05-2.46), P = 0.028; pooled HR for OS: 1.08 (95% CI: 0.55-2.10), P = 0.8). Pathologically negative SLN (SLN-) patients had better OS (pooled HR: 4.42 (95% CI: 1.82-10.7), P = 0.0009) and DFS (pooled HR: 2.58 (95% CI: 1.78-3.73)) as compared to SLN+ patients.
SLN mapping can provide strong prognostic information regarding OS and DFS in cN0 MCC patients. More importantly, SLN mapping can improve DFS and possibly OS in cN0 MCC patients as compared to nodal observation. As MCC is a rare tumor, large multicenter prospective studies are still needed to validate the survival benefit of SLN mapping.
PubMed and SCOPUS databases were searched by using "Merkel AND sentinel" as keywords. All studies with prognostic information regarding SLN mapping in cN0 MCC patients were included. Hazard ratio (HR) for overall survival (OS) and disease free survival (DFS) was used as effect size.
SLN biopsy predicted better DFS and OS as compared to the nodal observation in cN0 MCC patients (pooled HR for DFS: 1.61 (95% CI: 1.05-2.46), P = 0.028; pooled HR for OS: 1.08 (95% CI: 0.55-2.10), P = 0.8). Pathologically negative SLN (SLN-) patients had better OS (pooled HR: 4.42 (95% CI: 1.82-10.7), P = 0.0009) and DFS (pooled HR: 2.58 (95% CI: 1.78-3.73)) as compared to SLN+ patients.
SLN mapping can provide strong prognostic information regarding OS and DFS in cN0 MCC patients. More importantly, SLN mapping can improve DFS and possibly OS in cN0 MCC patients as compared to nodal observation. As MCC is a rare tumor, large multicenter prospective studies are still needed to validate the survival benefit of SLN mapping.
Keywords
Aged, Carcinoma, Merkel Cell/pathology, Disease-Free Survival, Female, Humans, Male, Prognosis, Sentinel Lymph Node Biopsy/methods, Skin Neoplasms/pathology
Pubmed
Web of science
Open Access
Yes
Create date
20/08/2017 19:05
Last modification date
20/08/2019 15:13
Usage data
